Chemclin Diagnostics Co. Ltd. A (688468) - Total Assets
Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) holds total assets worth CN¥1.76 Billion CNY (≈ $258.12 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Chemclin Diagnostics Co. Ltd. A cash conversion from operations for how efficiently the company converts equity into cash flow.
Chemclin Diagnostics Co. Ltd. A - Total Assets Trend (2017–2025)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See 688468 share price today for real-time trading data and today's change.
Chemclin Diagnostics Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Chemclin Diagnostics Co. Ltd. A's total assets of CN¥1.76 Billion consist of 43.3% current assets and 56.8% non-current assets. Explore Chemclin Diagnostics Co. Ltd. A short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.0% |
| Accounts Receivable | CN¥12.93 Million | 0.7% |
| Inventory | CN¥110.05 Million | 6.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥35.44 Million | 2.0% |
| Goodwill | CN¥153.76 Million | 8.7% |
Asset Composition Trend (2017–2025)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chemclin Diagnostics Co. Ltd. A's current assets represent 43.3% of total assets in 2025, a decrease from 59.3% in 2017.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, down from 22.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 21.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 8.7% of total assets.
Chemclin Diagnostics Co. Ltd. A Competitors by Total Assets
Key competitors of Chemclin Diagnostics Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.56 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
P&K Skin Research Center Co. Ltd
KQ:347740
|
Korea | ₩85.87 Billion |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
Chemclin Diagnostics Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.77 | 7.12 | 9.68 |
| Quick Ratio | 4.06 | 6.37 | 8.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥587.16 Million | CN¥902.51 Million | CN¥913.03 Million |
Chemclin Diagnostics Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Chemclin Diagnostics Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.73 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -3.9% |
| Total Assets | CN¥1.76 Billion |
| Market Capitalization | $386.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values Chemclin Diagnostics Co. Ltd. A's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Chemclin Diagnostics Co. Ltd. A's assets decreased by 3.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Chemclin Diagnostics Co. Ltd. A (2017–2025)
The table below shows the annual total assets of Chemclin Diagnostics Co. Ltd. A from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.76 Billion ≈ $257.68 Million |
-3.89% |
| 2024-12-31 | CN¥1.83 Billion ≈ $268.10 Million |
+0.64% |
| 2023-12-31 | CN¥1.82 Billion ≈ $266.41 Million |
+14.42% |
| 2022-12-31 | CN¥1.59 Billion ≈ $232.84 Million |
+11.20% |
| 2021-12-31 | CN¥1.43 Billion ≈ $209.39 Million |
+42.12% |
| 2020-12-31 | CN¥1.01 Billion ≈ $147.33 Million |
+1.35% |
| 2019-12-31 | CN¥993.39 Million ≈ $145.36 Million |
+16.02% |
| 2018-12-31 | CN¥856.25 Million ≈ $125.30 Million |
+20.05% |
| 2017-12-31 | CN¥713.24 Million ≈ $104.37 Million |
-- |
About Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more